<DOC>
	<DOCNO>NCT01489826</DOCNO>
	<brief_summary>This study trial Dexanabinol patient advance solid tumour . The purpose protocol study different dos study drug determine maximum safe dose understand safety study drug; understand body study drug; understand study drug body measure reduction size patient ' cancer tumour ( ) . Dexanabinol synthetic cannabinoid derivative reduce psychotropic potential initially investigated neuroprotective agent . Because method action however think may effect destroy cancer cell reduce level control networks prevent cancer cell die .</brief_summary>
	<brief_title>A Phase 1 Study Dexanabinol Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>HU 211</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>1 . Adult patient define age ≥18 year . 2 . Patients histologically cytologically confirm solid tumour advance , metastatic progressive , effective standard therapy available . 3 . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤2 . 4 . Any acute chronic adverse effect prior chemotherapy radiotherapy resolve &lt; Grade 2 determine Common Terminology Criteria Adverse Events ( CTCAE ) v4.03 criterion , exception alopecia . 5 . Evaluable disease , either measurable imaging , informative tumour marker ( ) , assess Response Evaluation Criteria In Solid Tumors ( RECIST ) v1.1 ( Eisenhauer , et al . 2009 ) . 6 . Laboratory value Screening : Absolute neutrophil count ≥1.5 x 109/L ; Platelets ≥100 x 109/L ; Total bilirubin &lt; 1.5 time upper limit normal ; Aspartate aminotransferase ( AST ) ≤2.5 time upper limit normal ; Alanine aminotransferase ( ALT ) ≤2.5 time upper limit normal ; Estimated glomerular filtration rate ( GFR ) &gt; 50 mL/min ( base Wright formula ( Wright , et al . 2001 ) ; Negative human chorionic gonadotropin ( hCG ) test woman childbearing potential ( defined woman ≤50 year age history amenorrhea ≤12 month prior study entry ) . Sexually active male female patient childbearing potential must agree use effective method birth control ( e.g . barrier method spermicide , oral parenteral contraceptive and/or intrauterine device ) entire duration study 1 month final administration Dexanabinol , patient must surgically sterile ( documentation patient 's medical record ) . 7 . If history treat brain metastasis , must clinically stable ≥4 week prior enrollment . 8 . Have life expectancy &gt; 3 month . 9 . Ability give write , informed consent prior studyspecific Screening procedure , understand consent may withdraw patient time without prejudice . 10 . Be willing able comply study protocol procedure . 1 . Patient pregnant breast feeding . 2 . History clinically significant cardiac condition , include ischemic cardiac event , myocardial infarction unstable cardiac disease within 3 month Cycle 1 , Day 1 . 3 . Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior Cycle 1 , Day 1 . Localised palliative radiotherapy permit symptom control . 4 . Major surgery within 6 week prior Cycle 1 , Day 1 . 5 . Known human immunodeficiency virus positivity . 6 . Active hepatitis B C active liver disease ( malignancy ) . 7 . Use investigational agent within 4 week Cycle 1 , Day 1 . 8 . Any active , clinically significant , viral , bacterial , systemic fungal infection within 4 week prior Cycle 1 , Day 1 . 9 . History significant chronic recurrent infection require treatment uncontrolled intercurrent illness would jeopardize patient safety , interfere objective protocol , limit patient compliance study requirement , determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cancer</keyword>
</DOC>